Zydus Cadila, an innovation-driven global pharmaceutical company, announced that the WHO INN committee has granted the name Desidustat to its Phase II anemia candidate, ZYAN1. The INN system aims to provide healthcare professionals with a unique and universal designated name for each pharmaceutical substance.
 
Anemia is a global public health problem affecting both developing and developed countries. Anemia commonly arises in kidney disease patients, because the kidneys no longer produce sufficient amounts of erythropoietin, a hormone which stimulates red blood cell production. Symptoms of anemia may include fatigue, skin pallor, shortness of breath, light-headedness, dizziness or a fast heartbeat. The Global ESA Market is estimated at USD 7 billion worldwide.
 
''In keeping with our mission of creating healthier communities globally, it is our constant endeavour to develop therapies that bridge unmet healthcare needs. Desidustat which is currently in the phase 2 clinical trials, strengthens this commitment with an aim to provide treatment to millions of patients suffering from anemia,'' said, Pankaj Patel, Chairman, Zydus Cadila.

Shares of the company gained Rs 4.75, or 1.06%, to trade at Rs 451.05. The total volume of shares traded was 55,496 at the BSE (12.38 p.m., Tuesday).